Vitexin / MFN2 Cancer Research Results

VT, Vitexin: Click to Expand ⟱
Features:

Vitexin - Apigenin-8-C-Glucoside

Alternative Names: Apigenin-8-C-glucoside, apigenin-8-C-β-D-glucopyranoside

Type: Flavone C-glycoside / apigenin derivative

Function: Vitexin is a naturally occurring C-glycosylated flavone in which glucose is attached to apigenin at the C-8 position. It exhibits antioxidant, anti-inflammatory, metabolic, cardiovascular, neuroprotective, and antiproliferative activities and can modulate pathways involving NF-κB, Nrf2/HO-1, MAPK, PI3K/AKT, AMPK, HIF-1α, apoptosis, and oxidative stress.

-see also IsoVitexin

Cancer: Preclinical studies indicate antiproliferative, pro-apoptotic, anti-migratory, anti-invasive, and anti-inflammatory effects across multiple cancer models. Reported mechanisms include modulation of PI3K/AKT, MAPK, NF-κB, HIF-1α, ROS, apoptosis, and cell-cycle signaling. Clinical anticancer efficacy has not been established.

Alzheimer's Disease: Preclinical evidence suggests neuroprotective activity through antioxidant and anti-inflammatory effects, reduction of neuronal injury, regulation of oxidative stress and mitochondrial function, and modulation of signaling pathways relevant to cognitive impairment and amyloid-associated neurotoxicity. Clinical efficacy for Alzheimer's disease has not been established.
MFN2, Mitofusin 2: Click to Expand ⟱
Source:
Type:

MFN1, MFN2, and OPA1 are mostly AD / neurodegeneration-relevant pathway targets: In AD, the general pattern is: fusion proteins MFN1, MFN2, and OPA1 tend to be reduced or functionally impaired, while fission signaling such as DRP1/FIS1 is often increased, contributing to fragmented mitochondria, synaptic injury, oxidative stress, and impaired bioenergetics

MFN1, MFN2, and OPA1 are mitochondrial fusion regulators. MFN1 and MFN2 mediate outer mitochondrial membrane fusion, while OPA1 mediates inner mitochondrial membrane fusion and helps maintain cristae structure. In Alzheimer’s disease and related neurodegenerative models, mitochondrial dynamics are commonly shifted toward excessive fragmentation, with reduced or impaired fusion signaling and increased fission stress. Restoring MFN2/OPA1/MFN1 activity may help preserve mitochondrial network integrity, oxidative phosphorylation, neuronal transport, calcium handling, and synaptic resilience.

Target / Pathway Primary Disease Relevance Normal Function Observed / Suspected Change in AD Therapeutic Direction Database Interpretation Evidence Strength Notes for Product Screening
MFN1 Mostly AD / neurodegeneration; secondary cancer relevance Outer mitochondrial membrane fusion protein. Works with MFN2 to tether and fuse adjacent mitochondria, helping maintain mitochondrial network integrity and mitochondrial DNA/protein complementation. Generally reported as reduced or functionally impaired in AD-related mitochondrial dynamics imbalance, contributing to mitochondrial fragmentation and reduced neuronal bioenergetic resilience. Support / restore mitochondrial fusion where excessive fission and mitochondrial fragmentation are present. Pathway target rather than product. Useful as part of a broader “mitochondrial fusion support” or “anti-fragmentation” pathway entry. Moderate Track products that increase MFN1 expression, improve mitochondrial network morphology, reduce DRP1-driven fragmentation, or restore fusion/fission balance.
MFN2 Strong AD / neurodegeneration relevance; also cancer and metabolic relevance Outer mitochondrial membrane fusion protein. Also involved in mitochondria-ER contact regulation, calcium handling, mitophagy-related quality control, mitochondrial trafficking, and cellular stress adaptation. MFN2 dysfunction or downregulation is associated with impaired mitochondrial fusion, abnormal mitochondria-ER communication, calcium stress, oxidative stress, synaptic vulnerability, and possibly amyloid/tau-associated mitochondrial injury. Usually upmodulation / restoration is desirable in AD models where mitochondrial fragmentation, poor transport, or excessive fission is present. High-priority AD target. Best entered as a mitochondrial dynamics, fusion, ER-mitochondria contact, and mitophagy-quality-control target. Moderate-Strong Track products that increase MFN2, improve mitochondrial elongation, reduce Aβ/tau-induced mitochondrial fragmentation, improve calcium homeostasis, or restore mitochondrial transport in neurons.
OPA1 Strong AD / neurodegeneration relevance; also apoptosis and cancer relevance Inner mitochondrial membrane fusion protein. Maintains cristae structure, supports oxidative phosphorylation, preserves mitochondrial membrane organization, and helps regulate cytochrome-c release during apoptosis. OPA1 loss or cleavage can reduce inner membrane fusion, destabilize cristae, impair oxidative phosphorylation, increase mitochondrial fragmentation, and sensitize neurons to synaptic and metabolic stress. Support / stabilize OPA1 activity, especially long-form fusion-active OPA1, where mitochondrial stress causes excessive OPA1 cleavage and fragmentation. High-priority AD target. Best entered under mitochondrial fusion, cristae integrity, oxidative phosphorylation, and apoptosis-resistance pathways. Moderate-Strong Track products that preserve OPA1, reduce pathological OPA1 cleavage, improve cristae integrity, improve ATP production, or reduce mitochondrial apoptosis signaling.


Scientific Papers found: Click to Expand⟱
7887- VT,  IVT,    Dietary Flavonoids Vitexin and Isovitexin: New Insights into Their Functional Roles in Human Health and Disease Prevention
- Review, AD, NA - Review, Var, NA
*antiOx↑, *Inflam↓, *AntiCan↑, *Bacteria↓, *neuroP↑, *Obesity↓, *cardioP↑, *ROS↓, *MMP↑, *ATP↑, *MFN2↑, *DRP1/DNM1L↓, *FOXO3↑, *NRF2↑, *Ferroptosis↓, *GPx4↑, TumCP↓, HMGB1↓, PI3K↓, Akt↓, Hif1a↓, CDK1↓, CycB/CCNB1↓, TumCCA↑, Apoptosis↑, P53↑, NF-kB↓, ERK↓, p‑PI3K↓, miR-34a↑, Apoptosis↑, CSCs?, *MAPK↓, *HO-1↑, *hepatoP↑, *AMPK↑, *Akt↑, *GSK‐3β↑, *chemoP↑, *Casp3↓, *IRes↝, *GlucoseCon↑, ChemoSen↑, *GSH↑, *SOD↑, *ATF2↑, *GPx↑, *GSTs↑, *AntiAge↑, *Stroke↓, *AChE↓, *ACE/ACE1↓, *ACE2↓, *GutMicro↑, *MPO↓, *H+/K+-ATPase↓, *AntiDiabetic↑, *GLUT4↑, *Obesity↓, *HH↓, *RenoP↑, *BioAv↓, *BioAv↝, *BioAv↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CycB/CCNB1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs?, 1,   ERK↓, 1,   miR-34a↑, 1,   PI3K↓, 1,   p‑PI3K↓, 1,  

Migration(tgid=13) ⓘ

TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

HMGB1↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

ACE/ACE1↓, 1,   ACE2↓, 1,   H+/K+-ATPase↓, 1,   IRes↝, 1,   Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Ferroptosis↓, 1,   GPx↑, 1,   GPx4↑, 1,   GSH↑, 1,   GSTs↑, 1,   HO-1↑, 1,   MFN2↑, 1,   MPO↓, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1,   DRP1/DNM1L↓, 1,   MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   GlucoseCon↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   ATF2↑, 1,   Casp3↓, 1,   Ferroptosis↓, 1,   MAPK↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

FOXO3↑, 1,   GSK‐3β↑, 1,   HH↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT4↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   BioAv↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiCan↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   Obesity↓, 2,   RenoP↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 47

Scientific Paper Hit Count for: MFN2, Mitofusin 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:462  Target#:1490  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page